# Palivizumab

## Synagis inj 50mg/0.5mL (sample)

| TAH Drug Code      | [ISYNA0](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISYNA0)                                                                                                                                                                                                                                                    |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Palivizumab can be used for high-risk infants with RSV disease， including those with bronchopulmonary dysplasia (BPD)， premature infants (?35 weeks gestation)， and infants with hemodynamically significant congenital heart disease (CHD)， to prevent severe lower respiratory tract disease caused by RSV infection. |
| Dosing             | IM， 15 mg/kg/month                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                               |
| Contraindications  | Previous significant hypersensitivity reaction to palivizumab.                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common: Rash (12%)， Fever (27%). Serious: Thrombocytopenia， Anaphylaxis， Hypersensitivity reaction.                                                                                                                                                                                                                      |
| Pregnancy          | No (Limited) Human Data – No Relevant Animal Data                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/palivizumab-drug-information)                                                                                                                                                                                                                                                  |

## Synagis inj 50mg/0.5mL

| TAH Drug Code      | [ISYNA1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISYNA1)                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease， including infants with bronchopulmonary dysplasia， a history of premature birth (<=35 weeks gestational age)， & children with hemodynamically significant congenital heart disease. |
| Dosing             | IM， 15 mg/kg/month.                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to palivizumab or humanized monoclonal antibodies.                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Upper respiratory infections， otitis media， rhinitis， rash， pain， hernia， increased SGOT， pharyngitis.                                                                                                                                                                                                                               |
| Pregnancy          | No (Limited) Human Data – No Relevant Animal Data                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/palivizumab-drug-information)                                                                                                                                                                                                                                                                  |

